HK1017270A1 - Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodies - Google Patents
Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodiesInfo
- Publication number
- HK1017270A1 HK1017270A1 HK99102534A HK99102534A HK1017270A1 HK 1017270 A1 HK1017270 A1 HK 1017270A1 HK 99102534 A HK99102534 A HK 99102534A HK 99102534 A HK99102534 A HK 99102534A HK 1017270 A1 HK1017270 A1 HK 1017270A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunizing
- vivo
- trispecific antibodies
- intact bispecific
- cells
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 abstract 4
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19725586A DE19725586C2 (de) | 1997-06-17 | 1997-06-17 | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1017270A1 true HK1017270A1 (en) | 1999-11-19 |
Family
ID=7832736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK99102534A HK1017270A1 (en) | 1997-06-17 | 1999-06-11 | Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodies |
Country Status (7)
Country | Link |
---|---|
US (2) | US7018632B2 (xx) |
EP (1) | EP0885614B1 (xx) |
JP (2) | JP4145995B2 (xx) |
AT (1) | ATE196607T1 (xx) |
DE (2) | DE19725586C2 (xx) |
DK (1) | DK0885614T3 (xx) |
HK (1) | HK1017270A1 (xx) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6805869B2 (en) | 1996-06-12 | 2004-10-19 | Shanghai Cp Guojian Pharmaceutical Co., Ltd. | Cellular vaccines and immunotherapeutics and methods for their preparation |
DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
WO2000018435A1 (de) * | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
DE10043437A1 (de) * | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
US8372409B2 (en) * | 2003-04-09 | 2013-02-12 | University Of Florida Research Foundation, Inc. | Dendritic cell binding proteins and uses thereof |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
EP1693448A4 (en) * | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
BRPI0415457A (pt) | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
US8066989B2 (en) * | 2004-11-30 | 2011-11-29 | Trion Pharma Gmbh | Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
ATE525400T1 (de) * | 2004-12-01 | 2011-10-15 | Trion Pharma Gmbh | Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
CA2957144C (en) * | 2005-04-08 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
DK1976886T3 (en) | 2005-12-16 | 2015-03-02 | Amgen Res Munich Gmbh | Means and methods for the treatment of tumor diseases |
EP1820513A1 (en) * | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US8252286B2 (en) * | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
TWI501976B (zh) * | 2007-05-21 | 2015-10-01 | Alder Biopharmaceuticals Inc | 抗TNF-α之抗體及其用途 |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US7935340B2 (en) * | 2007-05-21 | 2011-05-03 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8062864B2 (en) * | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
EP2033657A1 (de) * | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
EP4339294A2 (en) | 2007-09-26 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
WO2010151792A1 (en) | 2009-06-26 | 2010-12-29 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
WO2012071561A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
EP2709655B1 (en) | 2011-05-17 | 2018-11-14 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
EP2524699A1 (en) | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
EP2545948B1 (en) * | 2011-07-12 | 2014-04-16 | Sorin Group Italia S.r.l. | Dual chamber blood reservoir |
CN105408356A (zh) * | 2013-05-10 | 2016-03-16 | 努玛有限公司 | 双特异性构建体及其用于治疗多种疾病的用途 |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
NZ726520A (en) * | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
AU2017325240A1 (en) | 2016-09-06 | 2019-05-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
CN111108202A (zh) | 2017-09-29 | 2020-05-05 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
KR20200088440A (ko) * | 2017-11-21 | 2020-07-22 | 노파르티스 아게 | 종양-연관 항원에 대한 삼중특이성 결합 분자 및 이의 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US6071517A (en) * | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
US4844893A (en) * | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
DE4407538C1 (de) * | 1994-03-07 | 1995-02-23 | Deutsches Krebsforsch | Bindungsreagens für Zell-Oberflächenprotein und Effektorzelle |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
DE19649223C2 (de) * | 1996-09-03 | 1998-07-30 | Gsf Forschungszentrum Umwelt | Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern |
DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
-
1997
- 1997-06-17 DE DE19725586A patent/DE19725586C2/de not_active Expired - Fee Related
-
1998
- 1998-06-15 US US09/094,921 patent/US7018632B2/en not_active Expired - Fee Related
- 1998-06-16 AT AT98110972T patent/ATE196607T1/de active
- 1998-06-16 DK DK98110972T patent/DK0885614T3/da active
- 1998-06-16 EP EP98110972A patent/EP0885614B1/de not_active Expired - Lifetime
- 1998-06-16 DE DE59800285T patent/DE59800285D1/de not_active Expired - Lifetime
- 1998-06-17 JP JP17038998A patent/JP4145995B2/ja not_active Expired - Fee Related
-
1999
- 1999-06-11 HK HK99102534A patent/HK1017270A1/xx not_active IP Right Cessation
-
2005
- 2005-07-20 US US11/186,136 patent/US8012470B2/en not_active Expired - Fee Related
-
2008
- 2008-03-13 JP JP2008064726A patent/JP2008189678A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0885614B1 (de) | 2000-09-27 |
EP0885614A2 (de) | 1998-12-23 |
DE59800285D1 (de) | 2000-11-02 |
US8012470B2 (en) | 2011-09-06 |
US20020009430A1 (en) | 2002-01-24 |
DE19725586C2 (de) | 1999-06-24 |
EP0885614A3 (de) | 1999-01-13 |
JPH1171288A (ja) | 1999-03-16 |
US20050255110A1 (en) | 2005-11-17 |
DK0885614T3 (da) | 2000-12-04 |
ATE196607T1 (de) | 2000-10-15 |
JP2008189678A (ja) | 2008-08-21 |
JP4145995B2 (ja) | 2008-09-03 |
US7018632B2 (en) | 2006-03-28 |
DE19725586A1 (de) | 1998-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1017270A1 (en) | Method of ex vivo immunizing using heterologous intact bispecific and/or trispecific antibodies | |
Lanzavecchia et al. | The use of hybrid hybridomas to target human cytotoxic T lymphocytes | |
DK0826695T3 (da) | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer | |
DE69734109D1 (de) | Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung | |
ES2093778T3 (es) | Nuevos anticuerpos y metodos para su uso. | |
AU664801B2 (en) | Humanised antibodies | |
GR3036951T3 (en) | Cells with multiple altered epitopes on a surface antigen for use in transplantation | |
EP0679093A1 (en) | METHOD FOR PROVIDING AGENTS TO TARGET CELLS. | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
CA2163989A1 (en) | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies | |
HUP0100794A1 (hu) | Új eljárás humán antigén elleni receptorok előállítására, és azok alkalmazása | |
DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
ATE13198T1 (de) | Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren. | |
PT699755E (pt) | Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem | |
GR3030415T3 (en) | Platelet activating factor antagonists. | |
AU4690897A (en) | Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent | |
AU2709295A (en) | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen | |
WO1996040250A3 (en) | Platelet-specific chimeric immunoglobulin and methods of use therefor | |
DE3783002D1 (de) | Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega. | |
NZ335545A (en) | Monoclonal dendritic cell (DC)-specific antibodies that binds to DC activated antigen CMRF-56 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160616 |